Intellia Thera CS (NTLA)

$25.60 -0.29 (-1.12%)
Market Cap 2.78B
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 2,977,100
Avg Vol 5,834,922
Day's Range N/A - N/A
Shares Out 107.35M
Stochastic %K 58%
Beta 2.37
Analysts Strong Sell
Price Target $33.46

Company Profile

Intellia Therapeutics, Inc., a clinical-stage gene editing company, focuses on the development of curative genome editing treatments. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 that is in Phase 1/2 study for the treatment of hereditary angioedema. It also focusses on the research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune dis...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 285 6200
Address:
40 Erie Street, Suite 130, Cambridge, United States
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 4:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NTLA Current Share Price: $25.60 Contracts: $NTLA January 15, 2027 $27 Calls Scale in: $9.50- $11.61 Scale out: $14.77-$18.99 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
svertical1
svertical1 Oct. 24 at 4:43 PM
$IBRX $CADL $CRSP $NTLA $XBI Great article. Looks to me like Anktiva will become the holly grail of disease ‘combo treatments’. So even Pharma with lame treatment (Chemo, CPI’s, Radiation, etc) can improve PFS & OS! TAM=Trillions!
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 2:14 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NTLA Current Share Price: $25.83 Contracts: $NTLA January 15, 2027 $27 Calls Scale in: $9.16- $11.19 Scale out: $14.24-$18.32 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
KacperZeb
KacperZeb Oct. 23 at 9:42 PM
$NTLA $WGS I bought WGS at 30 dollars after an already spectacular run and then sold my shares at 36 dollars while WGS is currently at 120. Now Im holding NTLA shares at 21 dollars and Im not making the same mistake you can bet on that. Once it hits 60 I will sell around half and see what the market sentiment is then. I believe bloomberg will only catch on around that mark.
0 · Reply
cannontrades
cannontrades Oct. 23 at 8:10 PM
$PRME $NTLA Don't believe me? Just watch.
1 · Reply
Almondbutter
Almondbutter Oct. 23 at 4:58 PM
$NTLA October 31 coming
0 · Reply
cannontrades
cannontrades Oct. 23 at 2:41 PM
$PRME SUPER bullish on this. Great retest of 4.90-5.20 area in a textbook bull flag pattern. This will see 8's - high conviction here. Chart is looking better than $NTLA actually. I trimmed some over there and moved more to PRME as I think more % gain will be here in the next months
0 · Reply
KevinDaBull
KevinDaBull Oct. 23 at 2:12 PM
$CRSP I added 30 $80 Jan 2025 CRSP calls since the stock has come in. $NTLA has been hot until this week. Not sure if it will skyrocket or not with the HAE data (will it be a big enough sample for conclusive results) CPI tomorrow may come in a little hotter, expected or not.
1 · Reply
svertical1
svertical1 Oct. 23 at 4:54 AM
$IBRX $CADL $CRSP $NTLA $XBI Biotech next? PSS / ImmunityBio are Trump’s favorite! ‘one wonders if Trump isn't really f’g with the shorts and hoping to spark sequential squeezes across all high beta segments’ https://www.zerohedge.com/markets/if-millions-shorts-suddenly-cried-out-terror-trump-admin-take-equity-stakes-quantum
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 4:48 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NTLA Current Share Price: $24.58 Contracts: $NTLA January 15, 2027 $25 Calls Scale in: $9.31- $11.38 Scale out: $14.49-$18.63 Can Easily Capture: 60% ROI Blended DTE: 450 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Latest News on NTLA
Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Oct 24, 2025, 8:15 AM EDT - 1 day ago

Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 3, 2025, 4:01 PM EDT - 21 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Sep 25, 2025, 1:57 PM EDT - 4 weeks ago

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 25, 2025, 9:52 AM EDT - 4 weeks ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Sep 19, 2025, 2:31 PM EDT - 5 weeks ago

Intellia Therapeutics: Full Trial Enrollment Wows Market - Underlines Buy Thesis

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 18, 2025, 7:30 AM EDT - 5 weeks ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Why big players are pouring millions in THIS biotech stock

Sep 1, 2025, 8:43 AM EDT - 7 weeks ago

Why big players are pouring millions in THIS biotech stock

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Aug 15, 2025, 12:24 PM EDT - 2 months ago

Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:17 PM EDT - 2 months ago

Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 1, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jul 31, 2025, 7:30 AM EDT - 3 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR SRPT CABA NGNE QURE RCKT

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Jul 18, 2025, 8:00 AM EDT - 3 months ago

With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 15, 2025, 10:45 AM EDT - 4 months ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

May 29, 2025, 11:25 AM EDT - 5 months ago

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

I Missed The Quantum Rally - I Won't Miss The Next One

May 20, 2025, 5:47 AM EDT - 5 months ago

I Missed The Quantum Rally - I Won't Miss The Next One

AMSC AUTL CAPR CLPT EDIT VANI VERV

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 18, 2025, 7:25 AM EDT - 5 months ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

May 14, 2025, 1:57 PM EDT - 5 months ago

Intellia Therapeutics, Inc. (NTLA) BofA Securities 2025 Healthcare Conference (Transcript)

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

May 12, 2025, 9:07 AM EDT - 5 months ago

Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

May 8, 2025, 11:37 AM EDT - 6 months ago

Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

May 5, 2025, 4:44 AM EDT - 6 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

CRSP

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

May 1, 2025, 7:30 AM EDT - 6 months ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 6 months ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 6 months ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 10, 2025, 10:40 AM EDT - 7 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 7 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 1:03 PM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Apr 3, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Mar 28, 2025, 6:24 AM EDT - 7 months ago

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Mar 26, 2025, 7:30 AM EDT - 7 months ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 4:35 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NTLA Current Share Price: $25.60 Contracts: $NTLA January 15, 2027 $27 Calls Scale in: $9.50- $11.61 Scale out: $14.77-$18.99 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
svertical1
svertical1 Oct. 24 at 4:43 PM
$IBRX $CADL $CRSP $NTLA $XBI Great article. Looks to me like Anktiva will become the holly grail of disease ‘combo treatments’. So even Pharma with lame treatment (Chemo, CPI’s, Radiation, etc) can improve PFS & OS! TAM=Trillions!
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 24 at 2:14 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NTLA Current Share Price: $25.83 Contracts: $NTLA January 15, 2027 $27 Calls Scale in: $9.16- $11.19 Scale out: $14.24-$18.32 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
KacperZeb
KacperZeb Oct. 23 at 9:42 PM
$NTLA $WGS I bought WGS at 30 dollars after an already spectacular run and then sold my shares at 36 dollars while WGS is currently at 120. Now Im holding NTLA shares at 21 dollars and Im not making the same mistake you can bet on that. Once it hits 60 I will sell around half and see what the market sentiment is then. I believe bloomberg will only catch on around that mark.
0 · Reply
cannontrades
cannontrades Oct. 23 at 8:10 PM
$PRME $NTLA Don't believe me? Just watch.
1 · Reply
Almondbutter
Almondbutter Oct. 23 at 4:58 PM
$NTLA October 31 coming
0 · Reply
cannontrades
cannontrades Oct. 23 at 2:41 PM
$PRME SUPER bullish on this. Great retest of 4.90-5.20 area in a textbook bull flag pattern. This will see 8's - high conviction here. Chart is looking better than $NTLA actually. I trimmed some over there and moved more to PRME as I think more % gain will be here in the next months
0 · Reply
KevinDaBull
KevinDaBull Oct. 23 at 2:12 PM
$CRSP I added 30 $80 Jan 2025 CRSP calls since the stock has come in. $NTLA has been hot until this week. Not sure if it will skyrocket or not with the HAE data (will it be a big enough sample for conclusive results) CPI tomorrow may come in a little hotter, expected or not.
1 · Reply
svertical1
svertical1 Oct. 23 at 4:54 AM
$IBRX $CADL $CRSP $NTLA $XBI Biotech next? PSS / ImmunityBio are Trump’s favorite! ‘one wonders if Trump isn't really f’g with the shorts and hoping to spark sequential squeezes across all high beta segments’ https://www.zerohedge.com/markets/if-millions-shorts-suddenly-cried-out-terror-trump-admin-take-equity-stakes-quantum
1 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 23 at 4:48 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $NTLA Current Share Price: $24.58 Contracts: $NTLA January 15, 2027 $25 Calls Scale in: $9.31- $11.38 Scale out: $14.49-$18.63 Can Easily Capture: 60% ROI Blended DTE: 450 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
Dandelo
Dandelo Oct. 22 at 2:53 PM
$NTLA Buying more around $25. :) I'm also of the opinion that our banks & financial institutions are in the early stages of a liquidity crunch, and wouldn't be surprised if we dip further in the short term. Will be buying every dip...
0 · Reply
cannontrades
cannontrades Oct. 22 at 2:12 PM
$NTLA Chop chop higher highs. I want my 30's!
1 · Reply
Deejay47
Deejay47 Oct. 22 at 9:26 AM
$NTLA this feels almost too good setup to be true. Incredible company but at the same time incredible short interest. I am confident that Intellia will deliver and available shares have guaranteed buyers ;) Also, quick position update: Have not sold single share nor closed any (leap) call positions. When $100?!
0 · Reply
NeelArmstrong
NeelArmstrong Oct. 21 at 6:46 PM
$NTLA eyes from twenty six nine
0 · Reply
BillionerOfKing
BillionerOfKing Oct. 21 at 5:41 PM
$NTLA Current Stock Price: $27.72 Contracts to trade: $30 NTLA Nov 21 2025 Call Entry: $2.50 Exit: $3.60 ROI: 44% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
APman
APman Oct. 21 at 5:18 PM
$NTLA Anyone expecting a public offering this year?
1 · Reply
Sf249
Sf249 Oct. 21 at 3:48 PM
$TELO ugh added more loaded for a repeat of last nights after market run $EDIT , $NTLA $DNA
1 · Reply
johnnyjasper64
johnnyjasper64 Oct. 21 at 12:39 PM
$NTLA Do we see $30 today?
0 · Reply
Timetoflytodamoon
Timetoflytodamoon Oct. 21 at 12:09 PM
$DCGO DocGo Acquires Virtual Care Platform SteadyMD, Expands Telehealth Services Across All 50 States. $MARA $NTLA $NUAI all bullish!
0 · Reply
trading_insight
trading_insight Oct. 21 at 11:55 AM
$NTLA as well with a monster day. Same sector
0 · Reply
WycklyTrader
WycklyTrader Oct. 21 at 5:18 AM
$TXG potential gap fill at 20.00 with increasing revenues. $EXEL anticipating big bounce off 30.00 level. 52wk high momo watch:$ANRO (potential gap fill at 14.00), $SANA (cup and handle breakout), $NTLA. AIRS testing 52wk high SOS levels with high short interest...
0 · Reply
Morty752
Morty752 Oct. 20 at 11:28 PM
$NTLA Looks like it is headed for $35
0 · Reply